HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial

PURPOSE: In JACOB trial, pertuzumab added to trastuzumab-chemotherapy did not significantly improve survival of patients with HER2-positive metastatic gastric cancer, despite 3.3 months increase versus placebo. HER2 copy-number variation (CNV) and AMNESIA panel encompassing primary resistance altera...

Descripción completa

Detalles Bibliográficos
Autores principales: Pietrantonio, Filippo, Manca, Paolo, Bellomo, Sara Erika, Corso, Simona, Raimondi, Alessandra, Berrino, Enrico, Morano, Federica, Migliore, Cristina, Niger, Monica, Castagnoli, Lorenzo, Pupa, Serenella Maria, Marchiò, Caterina, Di Bartolomeo, Maria, Restuccia, Eleonora, Lambertini, Chiara, Tabernero, Josep, Giordano, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890129/
https://www.ncbi.nlm.nih.gov/pubmed/36413222
http://dx.doi.org/10.1158/1078-0432.CCR-22-2533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890129/
https://www.ncbi.nlm.nih.gov/pubmed/36413222
http://dx.doi.org/10.1158/1078-0432.CCR-22-2533

Ejemplares similares